Semin Vasc Med 2005; 05(4): 375-378
DOI: 10.1055/s-2005-922483
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

D-Dimer Testing in Pregnancy

Sabine Eichinger1
  • 1Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
Further Information

Publication History

Publication Date:
22 November 2005 (online)


Normal pregnancy is associated with alterations of the hemostatic system toward a hypercoagulable state. Elevated markers of coagulation and fibrinolytic system activation, such as D-dimer, indicate increased thrombin activity and increased fibrinolysis following fibrin formation throughout pregnancy. Testing for D-dimer in pregnant women could be useful for the diagnosis and prediction of a venous thromboembolic event or pregnancy-related complications and for monitoring antithrombotic treatment. This approach, however, is hampered by the fact that even an uncomplicated pregnancy in healthy women is accompanied by a substantial increase of D-dimer. Thus, prior to clinical application reference values of D-dimer according to gestational age need to be validated. A substantial increase of D-dimer during pregnancy is seen despite thromboprophylaxis with low-molecular-weight heparin (LMWH), indicating that further studies are needed to evaluate monitoring of LMWH during pregnancy and to investigate the optimal beginning and dose of LMWH thromboprophylaxis in pregnant women.


  • 1 Koonin L M, MacKay A P, Berg C J, Atrash H K, Smith J C. Pregnancy-related mortality surveillance-United States, 1987-1990.  MMWR CDC Surveill Summ. 1997;  46 17-36
  • 2 Greer I A. Thrombosis in pregnancy: maternal and fetal issues.  Lancet. 1999;  353 1258-1265
  • 3 Ginsberg J S, Brill-Edwards P, Burrows R F et al.. Venous thrombosis during pregnancy: leg and trimester of presentation.  Thromb Haemost. 1992;  67 519-520
  • 4 Rosendaal F R. Risk factors for venous thrombotic disease.  Thromb Haemost. 1999;  82 610-619
  • 5 Hellgren M. Hemostasis during normal pregnancy and puerperium.  Semin Thromb Hemost. 2003;  29 125-130
  • 6 Eichinger S, Weltermann A, Philipp K et al.. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.  Thromb Haemost. 1999;  82 1232-1236
  • 7 Bar J, Blickstein D, Hod M, Bar-Hava I. Increased D-dimer levels in twin gestation.  Thromb Res. 2000;  98 485-489
  • 8 Wells P S, Anderson D R, Ginsberg J. Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and noninvasive diagnostic tests.  Semin Thromb Hemost. 2000;  26 643-656
  • 9 Kelly J, Hunt B J. A clinical probability assessment and D-dimer measurement should be the initial step in the investigation of suspected venous thromboembolism.  Chest. 2003;  124 1116-1119
  • 10 Van Wersch JWJ, Ubachs JMH. Blood coagulation and fibrinolysis during normal pregnancy.  Eur J Clin Chem Clin Biochem. 1991;  29 45-50
  • 11 Sattar N, Greer I A, Rumley A et al.. A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy.  Thromb Haemost. 1999;  81 71-75
  • 12 Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerlosse P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery.  Br J Haematol. 2001;  115 150-152
  • 13 Giavarina D, Mezzana G, Dorizzi R M, Soffiati G. Reference interval of D-dimer in pregnant women.  Clin Biochem. 2001;  34 331-333
  • 14 Morse M. Establishing a normal range for D-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis.  J Thromb Haemost. 2004;  2 1202-1204
  • 15 Epiney M, Boehlen F, Boulvain M, Reber G, Antonelli E, de Moerloose P. D-dimer levels during delivery and the postpartum.  J Thromb Haemost. 2005;  3 268-271
  • 16 Brill-Edwards P, Ginsberg J S, Gent M et al.. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group.  N Engl J Med. 2000;  343 1439-1444
  • 17 Pabinger I, Grafenhofer H, Kyrle P A et al.. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism.  Blood. 2002;  100 1060-1062
  • 18 Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.  Thromb Haemost. 2002;  87 7-12
  • 19 Eichinger S, Minar E, Bialonczyk C et al.. D-dimer levels and risk of recurrent venous thromboembolism.  JAMA. 2003;  290 1071-1074
  • 20 Cadroy Y, Grandjean H, Pichon J et al.. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia.  Br J Obstet Gynaecol. 1993;  100 416-420
  • 21 Bellart J, Gilabert R, Fontcuberta J, Carreras E, Miralles R M, Cabero L. Coagulation and fibrinolysis parameters in normal pregnancy and in gestational diabetes.  Am J Perinatol. 1998;  15 479-486
  • 22 Proietti A B, Johnson M J, Proietti F A, Repke J T, Bell W R. Assessment of fibrin(ogen) degradation products in preeclampsia using immunoblot, enzyme-linked immunosorbent assay, and latex-based agglutination.  Obstet Gynecol. 1991;  77 696-700
  • 23 Bellart J, Gilabert R, Angles A et al.. Tissue factor levels and high ratio of fibrinopeptide A: D-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia.  Br J Obstet Gynaecol. 1999;  106 594-597
  • 24 Nolan T E, Smith R P, Devoe L D. Maternal plasma D-dimer levels in normal and complicated pregnancies.  Obstet Gynecol. 1993;  81 235-238
  • 25 Nolan T E, Smith R P, Devoe L D. A rapid test for abruptio placentae: evaluation of a D-dimer latex agglutination slide test.  Am J Obstet Gynecol. 1993;  169 265-268; discussion 268-269
  • 26 Padden M O. HELLP syndrome: recognition and perinatal management.  Am Fam Physician. 1999;  60 829-836, 839 (Review)
  • 27 Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Predictive values of coagulation/fibrinolysis parameters for the termination of pregnancy complicated by severe preeclampsia.  Semin Thromb Hemost. 2001;  27 137-141
  • 28 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.  Thromb Haemost. 2000;  83 693-697
  • 29 Nelson-Piercy C, Letsky E A, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.  Am J Obstet Gynecol. 1997;  176 1062-1068
  • 30 Hunt B J, Doughty H A, Majumdar G et al.. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.  Thromb Haemost. 1997;  77 39-43
  • 31 Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia.  J Thromb Haemost. 2003;  1 433-438
  • 32 Gris J C, Mercier E, Quere I et al.. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.  Blood. 2004;  103 3695-3699
  • 33 Hoke M, Kyrle P A, Philipp K et al.. Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin.  Thromb Haemost. 2004;  91 935-940

Sabine EichingerM.D. 

Department of Internal Medicine I, Medical University of Vienna

Waehringer Guertel 18-20, 1090 Vienna, Austria